BRIEF-Rallybio Announces Initiation Of Phase 2 Clinical Trial Of RLYB212

Reuters11-21

Nov 21 (Reuters) - Rallybio Corp RLYB.O:

RALLYBIO ANNOUNCES INITIATION OF PHASE 2 CLINICAL TRIAL OF RLYB212
RALLYBIO CORP - PHASE 2 TRIAL TO ASSESS PK AND SAFETY OF RLYB212
RALLYBIO CORP - TRIAL TO ENROLL PARTICIPANTS IN BELGIUM, NETHERLANDS, NORWAY, SWEDEN, UK

Source text: ID:nBw8vrdhZa

Further company coverage: RLYB.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2485495819?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-21 21:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2485495819","market":"us","top_or_hot":-1,"title":"BRIEF-Rallybio Announces Initiation Of Phase 2 Clinical Trial Of RLYB212","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Rallybio Announces Initiation Of Phase 2 Clinical Trial Of RLYB212</title></head><body><p><span>Nov 21 (Reuters)</span><span> - </span>Rallybio Corp <span>RLYB.O</span>:</p><ul><li><p>RALLYBIO ANNOUNCES INITIATION OF PHASE 2 CLINICAL TRIAL OF RLYB212</p></li><li><p>RALLYBIO CORP - PHASE 2 TRIAL TO ASSESS PK AND SAFETY OF RLYB212</p></li><li><p>RALLYBIO CORP - TRIAL TO ENROLL PARTICIPANTS IN BELGIUM, NETHERLANDS, NORWAY, SWEDEN, UK</p></li></ul><p>Source text: <span>ID:nBw8vrdhZa</span></p><p>Further company coverage: <span>RLYB.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Rallybio Announces Initiation Of Phase 2 Clinical Trial Of RLYB212</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Rallybio Announces Initiation Of Phase 2 Clinical Trial Of RLYB212\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-21 21:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nTUA8JQ0PR:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRIEF-Rallybio Announces Initiation Of Phase 2 Clinical Trial Of RLYB212Nov 21 (Reuters) - Rallybio Corp RLYB.O:RALLYBIO ANNOUNCES INITIATION OF PHASE 2 CLINICAL TRIAL OF RLYB212RALLYBIO CORP - PHASE ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nTUA8JQ0PR:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RLYB","symbol_name":"Rallybio Corp.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nTUA8JQ0PR:1","article_id":"2485495819","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485495819","pubTimestamp":1732194393,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Rallybio Announces Initiation Of Phase 2 Clinical Trial Of RLYB212Nov 21 (Reuters) - Rallybio Corp RLYB.O:RALLYBIO ANNOUNCES INITIATION OF PHASE 2 CLINICAL TRIAL OF RLYB212RALLYBIO CORP - PHASE ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RLYB":"Rallybio Corp.","BK4539":"次新股","BK4139":"生物科技"},"translate_title":"简报-Rallybio宣布启动RLYB212的2期临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RLYB":0.9},"content_text":"BRIEF-Rallybio Announces Initiation Of Phase 2 Clinical Trial Of RLYB212Nov 21 (Reuters) - Rallybio Corp RLYB.O:RALLYBIO ANNOUNCES INITIATION OF PHASE 2 CLINICAL TRIAL OF RLYB212RALLYBIO CORP - PHASE 2 TRIAL TO ASSESS PK AND SAFETY OF RLYB212RALLYBIO CORP - TRIAL TO ENROLL PARTICIPANTS IN BELGIUM, NETHERLANDS, NORWAY, SWEDEN, UKSource text: ID:nBw8vrdhZaFurther company coverage: RLYB.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2485495819"}